Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2012

View Archived Issues

Novel compounds acting on urate transporter patented by Ardea Bisociences

Multigene biomarker panels predict early-stage atherosclerosis

MicroRNA expression signature helps predict response to anticancer agent

Clinical data published on prucalopride for chronic intestinal pseudo-obstruction

Jazz Pharmaceuticals merges with Azur Pharma

Constellation Pharmaceuticals enters collaboration

Joint research agreement targets novel biofocused anticancer therapies

Study identifies mediator of drug-induced liver injury and agent to target it

Milestone developments for Novartis' Lucentis and Galvus in China

Novel tyrosine-protein kinase BTK inhibitors disclosed by Bristol-Myers Squibb

Avixgen patents new candidate drugs for HIV infection

Scientists at PAION prepare novel antifibrinolytic thrombomodulin analogues

Altos Therapeutics presents new dopamine receptor antagonists

PROLOR Biotech presents topline data on hGH-CTP

Phase I trial starts for Celldex Therapeutics' CDX-301

Bristol-Myers Squibb patents novel HIV attachment inhibitors

XOMA acquires U.S. rights to Servier franchise

Concert Pharmaceuticals synthesizes novel HCV NS5B inhibitors

Treatment begins in first FDA-cleared Cavatak trial

Research further delineates Kevetrin's mechanism of action

Soligenix reports results on anthrax vaccine

Provectus receives regulatory guidance from FDA for PV-10

FDA approves new pediatric formulations of Viread

FDA issues complete response letter regarding dapagliflozin

Protalex advances phase Ib study of PRTX-100

Wilex completes phase I trial of oral MEK inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...